Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience Biomedicals's gross profit for the
six
months ended in Mar. 2025 was ₹181.7 Mil. Avience Biomedicals's gross profit for the trailing twelve months (TTM) ended in Mar. 2025 was ₹181.7 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Avience Biomedicals had a gross margin of 40.17% for the quarter that ended in Mar. 2025 => Durable competitive advantage
Avience Biomedicals Gross Profit Related Terms
Avience Biomedicals Gross Profit Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals Gross Profit Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
Gross Profit
31.41
83.76
181.73
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
Gross Profit
31.41
83.76
181.73
NSE:AVIENCE vs ABT, SYK, MDT: Gross Profit Comparison
For the Medical Devices subindustry, Avience Biomedicals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Gross Profit distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's Gross Profit falls into.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Mar. 2025 was ₹181.7 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Avience Biomedicals (NSE:AVIENCE) has a Gross Profit of ₹181.7 Mil as of Mar. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Avience Biomedicals and its competitors.
Is Avience Biomedicals' Gross Profit too high?
Avience Biomedicals' current Gross Profit is ₹181.7 Mil. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Gross Profit compare to ABT and SYK?
Avience Biomedicals' Gross Profit of ₹181.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Avience Biomedicals and its competitors. Avience Biomedicals's current Gross Profit is ₹181.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Gross Profit of ₹181.7 Mil. The current Gross Profit is ₹181.7 Mil. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Gross Profit is ₹181.7 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
